High flow nasal cannula oxygen therapy in acute respiratory failure from acute exacerbation of fibrotic interstitial lung disease

Authors

  • Fernanda Machado Balzan Hospital de Clínicas de Porto Alegre
  • Eder Chaves Pacheco Laboratório de Pneumologia LIM-09, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo,
  • Fernando Nataniel Vieira Hospital de Clínicas de Porto Alegre
  • Joares Luiz moretti Jr Hospital de Clínicas de Porto Alegre
  • Bruna Maciel Catarino
  • Augusto Savi Hospital de Clínicas de Porto Alegre

Keywords:

respiratory failure, interstitial lung disease, high flow nasal cannula

Abstract

Introduction. High flow nasal cannula oxygen therapy (HFNC) has become frequent in the treatment of patients with acute hypoxemic respiratory failure. Methods. Eleven patients with acute exacerbation of fibrotic interstitial lung disease (ILD) were treated with HFNC after failure of conventional therapy (SatO2< 90% offering 100% FiO2 by non-rebreathing mask or noninvasive ventilation). Results. Ten patients had success with HFNC (not requiring orotracheal intubation) during emergency department admission. HFNC significantly improves clinical variables after 2h: respiratory rate decreased from 33 ± 6 breaths/min to 23 ± 3 breaths/min; PaO2 increased from 48.7 (38 - 59)mmHg to 81.1 (76 - 90) mmHg; PaO2/FiO2 ratio increased from 102.4 ± 32.2 to 136.6 ± 29.4; SatO2 increased from 85 (66 - 92)% to 96 ± (95 - 97)%. HFNC could be an effective alternative in the treatment of acute respiratory failure from acute exacerbations of fibrotic ILD.

Downloads

Download data is not yet available.

Downloads

Published

2020-07-15

How to Cite

1.
Balzan FM, Pacheco EC, Vieira FN, moretti Jr JL, Catarino BM, Savi A. High flow nasal cannula oxygen therapy in acute respiratory failure from acute exacerbation of fibrotic interstitial lung disease. Clin Biomed Res [Internet]. 2020 Jul. 15 [cited 2025 Apr. 29];40(1). Available from: https://seer.ufrgs.br/index.php/hcpa/article/view/98187

Issue

Vol. 40 No. 1 (2020): Clinical and Biomedical Research

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).